source
- Roche signs $2 billion deal with Atavistik to discover allosteric cardiovascular-renal-metabolic drugsRoche announced a partnership with Cambridge-based biotech Atavistik Bio to develop allosteric small-molecule therapies for cardiovascular, renal and metabolic diseases. The agreement includes an u…
- Eli Lilly commits $100M upfront in new five-target partnership with China's InnoCareEli Lilly has agreed to pay $100 million upfront and in the near term to Chinese biotech InnoCare Pharma as part of a five‑target drug discovery partnership. The agreement also provides for up to $…